MedTrace Logo

Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation

NCT02702427 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2019-05-09

No results posted yet for this study

Summary

Invasive infections with CMV and Adenovirus, not responding to virostatic treatment are treated with virusspecific donor derived or autologous virusspecific T-cells.

Conditions

  • Cytomegalovirus Infection
  • Adenovirus Infection

Interventions

BIOLOGICAL

virus-specific T-Cells

infusion

Sponsors & Collaborators

  • St. Anna Kinderkrebsforschung

    lead OTHER

Principal Investigators

  • Susanne Matthes, MD · St. Anna Kinderkrebsforschung

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-03
Primary Completion
2019-04-01
Completion
2019-04-01

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702427 on ClinicalTrials.gov